CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Contributers

Recommended Insights

Factors to Employ Whilst Evaluating a...

Shahin Farshchi, Partner, Lux Capital

Recent Trends In The Startup Landscape

Al Sambar, General Partner, XRC Labs

Brave New World - A Glance at the Startup...

Sam Colella, VC, Versant Ventures

The Changing Geography of the Venture Capital

Fernando Rivera, Managing Partner, BuenTrip Ventures

The Importance of Being an Active Investor

Glenn Rieger, General Partner, NewSpring Capital

Intricacies of Precision Medicine

Andrew Garrett, PhD, Executive Vice President,...

Startups In The Coronavirus Era: The...

Tai Nicolopoulos, Head of Marketing, SeedInvest

Iot - Back To The Past - And Into Last...

Dov Moran, Managing Partner, Grove Ventures

Factors to Employ Whilst Evaluating a...

Shahin Farshchi, Partner, Lux Capital

Recent Trends In The Startup Landscape

Al Sambar, General Partner, XRC Labs

Brave New World - A Glance at the Startup...

Sam Colella, VC, Versant Ventures

The Changing Geography of the Venture Capital

Fernando Rivera, Managing Partner, BuenTrip Ventures

The Importance of Being an Active Investor

Glenn Rieger, General Partner, NewSpring Capital

Intricacies of Precision Medicine

Andrew Garrett, PhD, Executive Vice President,...

Startups In The Coronavirus Era: The...

Tai Nicolopoulos, Head of Marketing, SeedInvest

Iot - Back To The Past - And Into Last...

Dov Moran, Managing Partner, Grove Ventures

How Recent Technology Transformations In Pharma Analytics Impact Business

Silji Abraham, Senior Vice President & Chief Digital and Transformation Officer, West Pharmaceutical Services
Tweet

Analytics has a long history of existence in different forms and practice. From the beginning, people predicted things about the future—predicting rain for the afternoon based on seeing clouds in the sky was perhaps one of the earliest forms of predicting. While computing and digitally capturing of data occurred later in history, we can easily assume that human brains were doing analytics and decision-making in everyday living throughout the history of mankind. The question has always been how much and how accurately into the future one can predict.


Analytics has the capability to not just tell us what is happening, but more importantly, why it is happening and whether it is likely to happen again. We can certainly agree that analytics is a phenomenon at scale today, which is applied in every aspect of life and business with the ability to digitize data and the democratization of computing. Almost all business decisions being made today are driven by some underlying analytics so that individuals can make decisions and hypotheses based on data rather than just human intuition. When you can truly rely on data that requires less human involvement, the analytics are highly predictable and reliable.


The fusion of computation and biology is indeed the new frontier of analytics/machine learning and is being pursued by almost all cutting-edge research in life science and healthcare. Today, we have the ability to digitize human genome at scale. Think about the possibility of looking into more than 3 billion base pairs of genetic codes of millions/billions of people! It is certainly an exciting possibility for analytics/machine learning and discovery. We are at the beginnings of personalized care in the world of healthcare by simply being able to unravel the mystery of the genetic codes, which dictate every aspect and characteristic of each of us and, until recently, have been an unknowable mystery of nature. 


The market is witnessing many instances of joining hands between tech companies and life science/Pharma companies to pursue the fusion of biology and computing. Molecular biology is a science focused on learning the complexities of nature and cell using computing, and analytics has helped tremendously on this journey.


"The fusion of computation and biology is indeed the new frontier of analytics/ machine learning and is being pursued by almost all cutting-edge research in life science and healthcare"


The future for life science and healthcare is indeed very fascinating and promising with the fusion of computing at scale, machine learning/artificial intelligence with algorithmic maturity, and techniques and opportunity to digitize molecular biology and proteomics. We will continue to see transformational progress in the coming decades, especially in the following three areas in life science and healthcare:


1. Generative chemistry powered by artificial intelligence/ machine learning will enable finding molecules with certain potential therapeutic characteristics to cure or treat more diseases.


2. Ability to perfect the manufacturing and delivery of the evolving cell and gene therapy with digitization of molecular biology and proteomics.


3. A world of connected humans with biosensors with non-intrusive form factors that continuously read vitals or life sustaining functions abstracted as signals and do edge computing and analytics to predict what is required to maintain good health, just like preventive maintenance for machines.


While we may never be able to unlock all the secrets of nature, we are indeed gearing up for an era with the potential ability to fight the worst diseases of nature, which too often lead to premature death for too many.


Weekly Brief

loading
Top 10 Biotech Startups Companies - 2022
> <
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2021

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2021

    Top Vendors

    Current Issue

Read Also

Achieving trial master file quality, timeliness and completeness

Susan K. Maue, Designation : Managing Director PharmaLex

Antibodies: The Building Blocks of Cures

John Armstrong, Head of Research; Head of BD; Global Strategic Programs; Global Straegic Marketing, Galderma

The Dynamic Commercial Aspects of Life Sciences

Jim Cooper, Director, Clinical Operations, Moderna

The Future of Life Sciences Industry

Matthew (Matt) Hewitt, Executive Director, Scientific Solutions C and GT, Charles River

Accelerating Digital Transformation through an Agile, Customer-centric Approach

Mark Mintz, Chief Information Officer at Charles River Laboratories

Re-imagining Learning in a Post-Pandemic World

Sebastian Teo, Head of Learning & Talent Management, Linde

Gene Therapy Clearly Communicated: The Importance of Patient-Centricity, Anan Omnichannel Approach, and Health Literacy

Tara Moroz, PhD Sr. Director, Genetic Medicine and Early Pipeline, Pfizer Inc.

Discovering the Medicines of the Future

Araz Raoof, Senior Vice President Global Drug Discovery & External Innovation at Ferring Pharmaceuticals
Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biotech-startups.lifesciencesreview.com/cxoinsight/how-recent-technology-transformations-in-pharma-analytics-impact-business-nwid-440.html